To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.
Erdafitinib — an oral pan-fibroblast growth factor receptor tyrosine kinase inhibitor (FGFR-TKI) — is the first targeted therapy for urothelial cancer.
Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.
Because tissue biopsy is not always possible in patients with mUC, identifying the optimal targeted therapy or clinical trial can be challenging.
The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
Patients diagnosed with MIBC are at a significant risk for death — which has not greatly improved in the last few decades.
The impact of this treatment on quality of life was not previously reported.
This study was designed to evaluate the efficacy of each treatment using 3-year distant metastasis-free survival as a primary outcome.
Of 542 enrolled patients, 270 were randomly assigned to pembrolizumab and 272 were assigned to chemotherapy. All patients progressed after platinum therapy.
The median follow-up was 17.6 months at time of interim analysis.
Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation.
A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.
As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.
Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.
While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.
Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.
The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.
A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.
A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.
Cancer cells may use increase p38 MAPK phosphorylation as a resistance mechanism in response to EGFR/HER2 inhibition.
In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.
From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.
Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.
Approximately 50% of patients with advanced urothelial carcinoma are unable to receive standard first-line cisplatin-based chemotherapy, indicating a need for additional treatment options.
In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.
Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.
Researchers randomly enrolled 530 patients with urothelial carcinoma who had progressed after platinum-based chemotherapy to receive ramucirumab plus docetaxel or placebo plus docetaxel.
The KEYNOTE-045 trial randomly assigned 542 patients with UC who progressed after 2 or fewer prior therapies to receive pembrolizumab or investigator's choice of paclitaxel, docetaxel, or vinflunine.
Cabozantinib and nivolumab (CaboNivo) with or without ipilimumab (Ipi) demonstrated manageable safety profiles and durable clinical activity.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy